CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AtheroNova Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AtheroNova Inc.
2301 Dupont Dr Ste 525
Phone: (949) 525-5471p:949 525-5471 IRVINE, CA  92612-7525  United States Ticker: AHROAHRO
This company is no longer actively traded on any major stock exchange.
Business Summary
AtheroNova Inc. is a clinical-stage biopharmaceutical company. The Company through its subsidiary, AtheroNova Operations, Inc., is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201412/31/2013YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
6552 Land subdividers and developers, except cemeteries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Thomas W.Gardner 60 5/13/2010 5/13/2010
Chief Financial Officer, Secretary MarkSelawski 58 5/13/2010 5/13/2010
Chief Operating Officer Randolph M.Johnson 60 3/31/2014 3/31/2014
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AHRO
AHROQ
AtheroNova Inc.
AtheroNova Operations, Inc.
Trist Holdings Inc
Z&Z Holdings, Inc.

General Information
Number of Employees: 3 (As of 12/31/2013)
Outstanding Shares: 8,809,139 (As of 11/10/2014)
Shareholders: 160
Stock Exchange: OTC
Federal Tax Id: 201915083
Fax Number: (302) 674-5266


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023